Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
With
Amgen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects who have a life expectancy of at least 12 weeks
Subjects with histologically or cytologically confirmed unresectable (Stage III) or metastatic (Stage IV) melanoma
Subjects must have progressed after receiving at least one cycle of DTIC or TMZ containing regimen
Subjects who have an ECOG PS of 0 or 1
Measurable disease defined as at least one lesion that can be accurately and serially measured per the modified RECIST criteria
You may not be if
Primary ocular or mucosal melanoma
Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta \[Noninvasive papillary carcinoma\], Tis \[Carcinoma in situ: "flat tumor"\]\& T1 \[Tumor invades subepithelial connective tissue\]) or any cancer curatively treated \< 5 years prior to study entry
History of cardiac disease
Known history of human immunodeficiency virus (HIV) infection
Clareo Health | A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
